Results 231 to 240 of about 1,991,569 (312)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.

JAMA Netw Open
Lei L, Wang B, Zhao L, Li J, Yan X, Jiang J, Wang L, Ren G, Li Y, Cheng X, Yan X, Zhu Y, Guo Y, Zhong H, Zhang H, Li J, BRAVO Collaborative Group.   +16 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Ethosuximide and Irritable Bowel Syndrome-Related Abdominal Pain: A Randomized Clinical Trial.

JAMA Netw Open
Kerckhove N, Zerbib F, Chambaz M, Mion F, Zalar A, Goutorbe F, Coffin B, Payen L, Roman S, Guilngar A, Pereira B, Dualé C, Dapoigny M, Melchior C, Scanzi J, IBSET Investigator Group (IIG) .   +15 more
europepmc   +1 more source

Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update. [PDF]

J Cachexia Sarcopenia Muscle
Fioretti F, von Haehling S, Coats AJS, Butler J, Del Fabbro E, Skipworth RJE, Laird BJA, Anker SD.   +7 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical Trial.

JAMA Netw Open
Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, Zhang L, Liu PP, Landsburg D, Clark AS, Shah PD, Hubbard RA, Huang A, Golec S, Hewitt M, Wilcox NS, Chen Z, Rethy L, Jung W, Ko K, Narayan V, Martei YM, Lang NN, Januzzi JL, Felker GM, Ky B.   +25 more
europepmc   +1 more source

WASOG Clinical Trial Endpoint Task Force: Executive Summary. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Baughman RP, Lower EE, Culver DA, Judson MA, Wells AU.   +4 more
europepmc   +1 more source

Comparison of Clinical Efficacy of Screw-retained Arch Bar vs Conventional Erich\'s Arch Bar in Maxillomandibular Fixation: A Randomized Clinical Trial

Heba Abo-Elfetouh Elsheikh, Mohamed Abdel-Monem Tawfik, Sally Awad, Merna Hosny Elhadidi   +3 more
openalex   +1 more source